قارن الطرق

	التقييم الروتيني لبيانات مؤشر المريض 3 (RAPID3)	مؤشر نشاط مرض التهاب الفقار اللاصق (BASDAI)
المجال	أمراض الروماتيزم	أمراض الروماتيزم
العائلة	Process / pipeline	Process / pipeline
سنة النشأة	2008	1994
صاحب الطريقة	Pincus et al.	Garrett et al.
النوع	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)
المصدر التأسيسي	Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.
الأسماء البديلة	RAPID3, RAPID-3	BASDAI, BAS-DAI
ذات صلة	3	4
الملخص	RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.